← Back to Search

Omega-3 Lipid Supplement

DHA-rich algal oil for Bronchopulmonary Dysplasia (MOBYDIck Trial)

Phase 3

Waitlist Available

Led By Anne-Monique Nuyt, MD, PhD

Research Sponsored by CHU de Quebec-Universite Laval

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age more than or equal to 16 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from first discharge or 40 weeks pma until 18-22 months ca

Awards & highlights

MOBYDIck Trial Summary

This trial will determine whether DHA supplementation in lactating mothers improves the chances of their infant surviving without bronchopulmonary dysplasia (BPD) at 36 weeks PMA.

Who is the study for?

This trial is for breastfeeding mothers aged 16 or older, who delivered pre-term (between 23 and less than 29 weeks of gestation) and plan to provide breast milk to their infants. Mothers can't join if they've been in another drug trial within the last 3 months, are taking high doses of DHA, or if their infant has significant birth defects.Check my eligibility

What is being tested?

The study tests whether DHA-rich algal oil given to lactating mothers helps prevent bronchopulmonary dysplasia in very premature infants. Participants are randomly divided into two groups: one receives DHA supplementation; the other gets a placebo.See study design

What are the potential side effects?

While specific side effects aren't listed for this trial, typical omega-3 supplement side effects may include fishy aftertaste, upset stomach, or bleeding issues. Placebos generally have no active ingredients but can cause perceived side effects.

MOBYDIck Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 16 years old or older.

MOBYDIck Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from first discharge or 40 weeks pma until 18-22 months ca

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from first discharge or 40 weeks pma until 18-22 months ca

This trial's timeline: 3 weeks for screening, Varies for treatment, and from first discharge or 40 weeks pma until 18-22 months ca for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

BPD-free survival

Secondary outcome measures

Any intraventricular hemorrhage and severe grade III or IV

Bronchopulmonary Dysplasia (BPD)

Mild, moderate and severe BPD

+8 more

Other outcome measures

Acceptability of a study at 8 years of age involving brain magnetic resonance imaging (MRI)

Behavioral problems

Blindness (yes/no), visual acuity +/- strabismus

+15 more

MOBYDIck Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: DHA-rich algal oilExperimental Treatment1 Intervention

1200mg DHA per day

Group II: PlaceboPlacebo Group1 Intervention

No supplementation in DHA

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

CHU de Quebec-Universite LavalLead Sponsor

167 Previous Clinical Trials

106,357 Total Patients Enrolled

1 Trials studying Bronchopulmonary Dysplasia

1,801 Patients Enrolled for Bronchopulmonary Dysplasia

Canadian Institutes of Health Research (CIHR)OTHER_GOV

1,341 Previous Clinical Trials

26,451,913 Total Patients Enrolled

4 Trials studying Bronchopulmonary Dysplasia

2,872 Patients Enrolled for Bronchopulmonary Dysplasia

Laval UniversityOTHER

417 Previous Clinical Trials

171,472 Total Patients Enrolled

1 Trials studying Bronchopulmonary Dysplasia

1,801 Patients Enrolled for Bronchopulmonary Dysplasia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there a great number of sites in North America where this research is taking place?

"At the moment, potential patients for this trial can go to IWK Health Centre in Halifax, Nova Scotia, Jewish General Centre in Montréal, Quebec, Victoria General Hospital in Victoria, Ontario, or any of the 16 other sites."

Answered by AI

What are the possible dangers of taking DHA-rich algal oil supplements?

"DHA-rich algal oil has undergone Phase 3 testing, so there is some data indicating that it is effective and multiple rounds of data supporting safety. Consequently, our team at Power gave it a score of 3."

Answered by AI

Recent research and studies

JamaJournal

Effect of Maternal Docosahexaenoic Acid Supplementation on Bronchopulmonary Dysplasia–free Survival in Breastfed Preterm Infants

Marc, Isabelle, Bruno Piedboeuf, Thierry Lacaze-Masmonteil, William Fraser, Benoît Mâsse, Ibrahim Mohamed, Mosarrat Qureshi, et al.. 2020. “Effect of Maternal Docosahexaenoic Acid Supplementation on Bronchopulmonary Dysplasia–free Survival in Breastfed Preterm Infants”. Jama. American Medical Association (AMA). doi:10.1001/jama.2020.8896.

BMJ OpenJournal

Effects of Maternal Docosahexaenoic Acid Supplementation on Brain Development and Neurodevelopmental Outcomes of Breastfed Preterm Neonates: Protocol for a Follow-up at Preschool Age of a Randomised Clinical Trial (mobydickps)

Guillot, Mireille, Carole-Anne Robitaille, Laurence Turner, Etienne Pronovost, Georges Caouette, Célia Matte-Gagné, François Olivier, et al.. 2022. “Effects of Maternal Docosahexaenoic Acid Supplementation on Brain Development and Neurodevelopmental Outcomes of Breastfed Preterm Neonates: Protocol for a Follow-up at Preschool Age of a Randomised Clinical Trial (mobydickps)”. BMJ Open. BMJ. doi:10.1136/bmjopen-2021-057482.

PediatricsJournal

Maternal High-dose DHA Supplementation and Neurodevelopment at 18–22 Months of Preterm Children

Guillot, Mireille, Anne Synnes, Etienne Pronovost, Mosarrat Qureshi, Thierry Daboval, Georges Caouette, François Olivier, et al.. 2022. “Maternal High-dose DHA Supplementation and Neurodevelopment at 18–22 Months of Preterm Children”. Pediatrics. American Academy of Pediatrics (AAP). doi:10.1542/peds.2021-055819.

Scientific ReportsJournal